Prevalence of Low Serum Alkaline Phosphatase and Hypophosphatasia in Adult Patients with Atypical Femur Fractures.
Alkaline Phosphatase
Atypical Femur Fracture
Bisphosphonates
Hypophosphatasia
Osteoporosis
Rare bone disease
Journal
Calcified tissue international
ISSN: 1432-0827
Titre abrégé: Calcif Tissue Int
Pays: United States
ID NLM: 7905481
Informations de publication
Date de publication:
06 2022
06 2022
Historique:
received:
18
10
2021
accepted:
17
01
2022
pubmed:
2
3
2022
medline:
18
5
2022
entrez:
1
3
2022
Statut:
ppublish
Résumé
Hypophosphatasia (HPP) is a rare genetic disorder characterized by low serum alkaline phosphatase (ALP), its manifestations may include atypical femoral fractures (AFF). However, the prevalence of low serum ALP and HPP in patients with AFF remains unknown. We retrospectively analyzed ALP levels and clinical manifestations compatible with HPP in 72 adult patients with confirmed AFF by chart review. ALP values were compared with those of a control group of patients with prior proximal femoral fracture during antiresorptive treatment (n = 20). Among the AFF patients, 18 (25%) had at least one serum ALP value ≤ 40 IU/L, although in all but one case, at least one ALP value > 40 IU/L was also detected at another time point. Most low ALP values were associated with antiresorptive treatment (P = 0.049) and lowest levels of ALP did not differ between the AFF and the control groups (P = 0.129). However, low ALP values among AFF patients were associated with a higher rate of bilateral AFF (50% vs 22%, P = 0.025), metatarsal fracture (33% vs 7%, P = 0.006), and with trends for more frequent use of glucocorticoid (22% vs 8%, P = 0.089) and proton pump inhibitor (61% vs 44%, P = 0.220). In one AFF patient with low ALP and clinical suspicion of HPP, a rare pathogenic heterozygous variant of the ALPL gene was identified. In conclusion, low ALP values are common among subjects with AFF and mainly related to concomitant antiresorptive medication. Hence, low serum ALP has low specificity for HPP among AFF patients.
Identifiants
pubmed: 35229197
doi: 10.1007/s00223-022-00949-1
pii: 10.1007/s00223-022-00949-1
pmc: PMC9108106
doi:
Substances chimiques
Alkaline Phosphatase
EC 3.1.3.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
703-711Informations de copyright
© 2022. The Author(s).
Références
JBMR Plus. 2018 Jan 03;2(1):1-11
pubmed: 30283886
Clin Biochem. 2009 Jun;42(9):885-91
pubmed: 19318027
Eur J Endocrinol. 2018 Mar;178(3):R81-R87
pubmed: 29339529
Osteoporos Int. 2018 Aug;29(8):1815-1825
pubmed: 29774402
Indian J Med Res. 2014 Jul;140(1):46-54
pubmed: 25222777
N Engl J Med. 2020 Aug 20;383(8):743-753
pubmed: 32813950
Biol Trace Elem Res. 2005 May;104(2):131-40
pubmed: 15894813
Int J Environ Res Public Health. 2019 May 05;16(9):
pubmed: 31060319
Int J Endocrinol. 2021 Jan 15;2021:8902367
pubmed: 33510787
Calcif Tissue Int. 2019 Jul;105(1):51-67
pubmed: 31006051
Calcif Tissue Int. 1995 Feb;56(2):109-12
pubmed: 7736317
Endocrine. 2018 Jul;61(1):7-16
pubmed: 29691807
J Bone Miner Res. 2019 Apr;34(4):579-604
pubmed: 30803025
Metabolism. 2013 Apr;62(4):518-26
pubmed: 23102518
N Engl J Med. 2014 Sep 4;371(10):974-6
pubmed: 25184886
Clin Biochem. 2013 Sep;46(13-14):1197-219
pubmed: 23578738
Nat Rev Endocrinol. 2016 Apr;12(4):233-46
pubmed: 26893260
Osteoporos Int. 2011 Jul;22(7):2211-2
pubmed: 20838769
Clin Chem. 2012 May;58(5):854-68
pubmed: 22371482
FEBS J. 2013 Oct;280(20):5052-64
pubmed: 23937530
J Bone Miner Res. 2009 Jun;24(6):1132-4
pubmed: 19113923
Proc Nutr Soc. 2008 May;67(2):157-62
pubmed: 18412989
Osteoporos Int. 2019 Jan;30(1):103-114
pubmed: 30539272
BMC Musculoskelet Disord. 2016 Aug 09;17:332
pubmed: 27507156
JAMA. 2006 Dec 27;296(24):2947-53
pubmed: 17190895
J Bone Miner Res. 2005 Jan;20(1):141-51
pubmed: 15619680
Thorax. 1992 Jun;47(6):418-20
pubmed: 1496499
J Bone Miner Res. 2014 Jan;29(1):1-23
pubmed: 23712442
Curr Osteoporos Rep. 2018 Aug;16(4):519-529
pubmed: 29951870